Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Tumor Virus Infections 1Spinocerebellar Degenerations 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Microsatellite Stable Colorectal Carcinoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Filgrastim 2venetoclax 1toripalimab 1spartalizumab 1resiquimod 1poly ICLC 1ivosidenib 1enasidenib 1durvalumab 1birinapant 1alanosine 1Topotecan 1Thiotepa 1Thalidomide 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Metformin 1Medicare Part B 1Leucovorin 1Irinotecan 1Ipilimumab 1Immunotherapy 1IFL protocol 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × Azacitidine × Gastrointestinal × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡